SEC Tracker
Get the app

Indivior Pharmaceuticals INDV

Indivior reports strong Q3 2026 results

Merger communication

Form
425
Filed
Importance
Routine
  1. Q3 2026 total net revenue of $356 million, up 13% YoY
  2. SUBLOCADE net revenue of $267 million, up 22% YoY
  3. Record net income of $137 million and non-GAAP net income of $161 million
  4. Expected merger with Supernus to close on November 2, 2026

Written from the 425 on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Indivior Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Apellis Pharmaceuticals APLS public float $1.8B, Jun 30, 2025
  2. Biocryst Pharmaceuticals BCRX public float $1.9B, Jun 30, 2025
  3. Agios Pharmaceuticals AGIO public float $1.9B, Jun 30, 2025
  4. Amicus Therapeutics FOLD public float $1.7B, Jun 30, 2025
  5. Supernus Pharmaceuticals SUPN public float $1.7B, Jun 30, 2025